{"id":7999,"date":"2016-02-15T00:00:00","date_gmt":"2016-02-14T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2016\/02\/15\/una-nova-estrategia-terapeutica-per-al-tumor-de-pulmo-mes-agressiu\/"},"modified":"2020-05-13T19:47:17","modified_gmt":"2020-05-13T17:47:17","slug":"una-nova-estrategia-terapeutica-per-al-tumor-de-pulmo-mes-agressiu","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2016\/02\/una-nova-estrategia-terapeutica-per-al-tumor-de-pulmo-mes-agressiu\/","title":{"rendered":"Una nova estrat\u00e8gia terap\u00e8utica per al tumor de pulm\u00f3 m\u00e9s agressiu"},"content":{"rendered":"

El c\u00e0ncer de pulm\u00f3 \u00e9s un dels m\u00e9s prevalents, amb m\u00e9s de 20.000 nous casos diagnosticats cada any a Espanya. En el 30% hi interv\u00e9 l’oncog\u00e8n KRAS, que fa que el tumor sigui m\u00e9s agressiu. Aix\u00ed mateix, \u00e9s un tipus de c\u00e0ncer de pulm\u00f3 que no compta amb ter\u00e0pies dirigides m\u00e9s enll\u00e0 de l’est\u00e0ndard amb cisplat\u00ed. <\/p>\n

Un estudi encap\u00e7alat pels investigadors Mariano Barbacid i David Santamaia, del Centre Nacional d’Investigacions Oncol\u00f2giques (CNIO), i en el qual tamb\u00e9 hi ha participat un equip de l’ICO-IDIBELL format per Alberto Villanueva i Ernest Nadal, ha identificat una possible nova estrat\u00e8gia per fer front a aquests tumors. <\/p>\n

L’estudi, que s’ha fet en models de ratolins, es publica a la revista Nature Medicine i mostra com la combinaci\u00f3 dirigida dels f\u00e0rmacs desatinib -inhibidors de la prote\u00efna DDR1- i demcizumab -un antic\u00f2s inhibidor de la via de Notch- redueix de forma espec\u00edfica i efica\u00e7 els tumors i millora substancialment el pron\u00f2stic i la superviv\u00e8ncia. Completats els estudis precl\u00ednics, el seg\u00fcent pas \u00e9s fer els assajos cl\u00ednics que validin la combinaci\u00f3 d’aquests f\u00e0rmacs per al tractament dels adenocarcinomes de pulm\u00f3. <\/p>\n

Els autors del treball han utilitzat models precl\u00ednics de ratol\u00ed modificats gen\u00e8ticament. Tamb\u00e9 s’han estudiat en orthoxenografts\u00ae de c\u00e0ncer de pulm\u00f3 que s\u00f3n models ortot\u00f2pics generats per l’implementaci\u00f3 de tumors humans en el pulm\u00f3 del ratol\u00ed, generats per l’equip d’Alberto Villanueva a l’ICO-IDIBELL\/Xenopat S.L. Aquests models, els m\u00e9s avan\u00e7ats que hi ha en c\u00e0ncer de pulm\u00f3, permeten estudiar l’efic\u00e0cia dels f\u00e0rmacs directament sobre mostres humanes.<\/p>\n","protected":false},"excerpt":{"rendered":"

El c\u00e0ncer de pulm\u00f3 \u00e9s un dels m\u00e9s prevalents, amb m\u00e9s de 20.000 nous casos diagnosticats cada any a Espanya. En el 30% hi interv\u00e9 l’oncog\u00e8n KRAS, que fa que el tumor sigui m\u00e9s agressiu. Aix\u00ed mateix, \u00e9s un tipus de c\u00e0ncer de pulm\u00f3 que no compta amb ter\u00e0pies dirigides m\u00e9s enll\u00e0 de l’est\u00e0ndard amb […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7999","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2025-01-01 09:56:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7999"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7999\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}